Ultragenyx Pharmaceutical...

NASDAQ: RARE · Real-Time Price · USD
29.96
0.95 (3.27%)
At close: Aug 15, 2025, 1:13 PM

Ultragenyx Pharmaceutical Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
560.23M 434.25M 363.33M 351.41M
Cost of Revenue
76.73M 45.21M 28.32M 16.01M
Gross Profit
483.5M 389.04M 335.01M 335.4M
Operating Income
-535.97M -569.21M -648.92M -381.74M
Interest Income
36.51M 26.69M 11.07M 1.93M
Pretax Income
-567.59M -608.46M -701.73M -452.98M
Net Income
-569.18M -606.64M -707.42M -454.02M
Selling & General & Admin
321.61M 309.8M 278.14M 219.98M
Research & Development
697.87M 648.45M 705.79M 497.15M
Other Expenses
n/a n/a 9.51M 241K
Operating Expenses
1.02B 958.25M 983.93M 717.13M
Interest Expense
63.04M 66M 43.02M 29.42M
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
1.1B 1B 1.01B 733.14M
Income Tax Expense
1.6M -1.82M 5.7M 1.04M
Shares Outstanding (Basic)
90.54M 73.54M 69.91M 67.8M
Shares Outstanding (Diluted)
90.54M 73.54M 69.91M 67.8M
EPS (Basic)
-6.29 -8.25 -10.12 -6.7
EPS (Diluted)
-6.29 -8.25 -10.12 -6.7
EBITDA
-469M -516.45M -640.51M -410.32M
EBIT
-504.55M -542.46M -658.71M -423.56M
Depreciation & Amortization
35.54M 26.01M 18.2M 13.24M